Report Information More information from: https ://www.wis eguyreports .com/reports /495874
Hairy Cell Leukemia - Pipeline Review, H1 2016 Report / Search Code: WGR495874
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Hairy Cell Leukemia - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Hairy Cell Leukemia - Pipeline Review, H1 2016’, provides an overview of the Hairy Cell Leukemia pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Hairy Cell Leukemia, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Hairy Cell Leukemia - The report reviews pipeline therapeutics for Hairy Cell Leukemia by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Hairy Cell Leukemia therapeutics and enlis ts all their major and minor projects - The report as s es s es Hairy Cell Leukemia therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Hairy Cell Leukemia Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Hairy Cell Leukemia - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hairy Cell Leukemia Overview 7 Therapeutics Development 8 Pipeline Products for Hairy Cell Leukemia - Overview 8 Hairy Cell Leukemia - Therapeutics under Development by Companies 9 Hairy Cell Leukemia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Hairy Cell Leukemia - Products under Development by Companies 14 Hairy Cell Leukemia - Companies Involved in Therapeutics Development 15 AbbVie Inc. 15 As tellas Pharma Inc. 16 As traZ eneca Plc 17 Biogenomics Limited 18 F. Hoffmann-La Roche Ltd. 19 Incyte Corporation 20 Juno Therapeutics Inc. 21 MedImmune, LLC 22 Novartis AG 23 Hairy Cell Leukemia - Therapeutics As s es s ment 24 As s es s ment by Monotherapy Products 24 As s es s ment by Combination Products 25 As s es s ment by Target 26 As s es s ment by Mechanis m of Action 28 As s es s ment by Route of Adminis tration 30 As s es s ment by Molecule Type 32 Drug Profiles 34 (INCB-039110 + INCB-040093) - Drug Profile 34 Product Des cription 34 Mechanis m of Action 34 R& D Progres s 34 AGS-67E - Drug Profile 35 Product Des cription 35 Mechanis m of Action 35 R& D Progres s 35 AZ D-6738 - Drug Profile 37 Product Des cription 37 Mechanis m of Action 37 R& D Progres s 37 dabrafenib mes ylate + trametinib dimethyl s ulfoxide - Drug Profile 39 Product Des cription 39 Mechanis m of Action 39 R& D Progres s 39 ibrutinib - Drug Profile 42 Product Des cription 42 Mechanis m of Action 42 R& D Progres s 42 INCB-40093 - Drug Profile 49 Product Des cription 49 Mechanis m of Action 49 R& D Progres s 49 INCB-50465 - Drug Profile 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50 interferon alfa-2a - Drug Profile 51 Product Des cription 51 Mechanis m of Action 51 R& D Progres s 51 interferon alfa-2b - Drug Profile 52 Product Des cription 52 Mechanis m of Action 52
R& D Progres s 52 interferon alfa-2b - Drug Profile 53 Product Des cription 53 Mechanis m of Action 53 R& D Progres s 53 itacitinib adipate - Drug Profile 54 Product Des cription 54 Mechanis m of Action 54 R& D Progres s 54 JCAR-015 - Drug Profile 56 Product Des cription 56 Mechanis m of Action 56 R& D Progres s 56 moxetumomab pas udotox - Drug Profile 58 Product Des cription 58 Mechanis m of Action 58 R& D Progres s 58 vemurafenib - Drug Profile 60 Product Des cription 60 Mechanis m of Action 60 R& D Progres s 60 Hairy Cell Leukemia - Recent Pipeline Updates 64 Hairy Cell Leukemia - Dormant Projects 97 Hairy Cell Leukemia - Dis continued Products 98 Hairy Cell Leukemia - Product Development Miles tones 99 Featured News & Pres s Releas es 99 May 16, 2013: As traZ eneca's MedImmune Enrolls Firs t Patient In Phas e III Leukemia Trial Of Moxetumomab Pas udotox 99 Appendix 100 Methodology 100 Coverage 100 Secondary Res earch 100 Primary Res earch 100 Expert Panel Validation 100 Contact Us 100 Dis claimer 101 Lis t of Tables Number of Products under Development for Hairy Cell Leukemia, H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Comparative Analys is by Late Stage Development, H1 2016 10 Comparative Analys is by Clinical Stage Development, H1 2016 11 Comparative Analys is by Early Stage Development, H1 2016 12 Comparative Analys is by Unknown Stage Development, H1 2016 13 Products under Development by Companies , H1 2016 14 Hairy Cell Leukemia - Pipeline by AbbVie Inc., H1 2016 15 Hairy Cell Leukemia - Pipeline by As tellas Pharma Inc., H1 2016 16 Hairy Cell Leukemia - Pipeline by As traZ eneca Plc, H1 2016 17 Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H1 2016 18 Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 19 Hairy Cell Leukemia - Pipeline by Incyte Corporation, H1 2016 20 Hairy Cell Leukemia - Pipeline by Juno Therapeutics Inc., H1 2016 21 Hairy Cell Leukemia - Pipeline by MedImmune, LLC, H1 2016 22 Hairy Cell Leukemia - Pipeline by Novartis AG, H1 2016 23 As s es s ment by Monotherapy Products , H1 2016 24 As s es s ment by Combination Products , H1 2016 25 Number of Products by Stage and Target, H1 2016 27 Number of Products by Stage and Mechanis m of Action, H1 2016 29 Number of Products by Stage and Route of Adminis tration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Hairy Cell Leukemia Therapeutics - Recent Pipeline Updates , H1 2016 64 Hairy Cell Leukemia - Dormant Projects , H1 2016 97 Hairy Cell Leukemia - Dis continued Products , H1 2016 98 Lis t of Figures Number of Products under Development for Hairy Cell Leukemia, H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Comparative Analys is by Clinical Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy Products , H1 2016 24 As s es s ment by Combination Products , H1 2016 25 Number of Products by Top 10 Targets , H1 2016 26 Number of Products by Stage and Top 10 Targets , H1 2016 26 Number of Products by Top 10 Mechanis m of Actions , H1 2016 28 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 28 Number of Products by Routes of Adminis tration, H1 2016 30 Number of Products by Stage and Routes of Adminis tration, H1 2016 30 Number of Products by Molecule Types , H1 2016 32 Number of Products by Stage and Molecule Types , H1 2016 32
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349